F
Faiz Niazi
Researcher at Novartis
Publications - 4
Citations - 671
Faiz Niazi is an academic researcher from Novartis. The author has contributed to research in topics: Neuroblastoma RAS viral oncogene homolog & Binimetinib. The author has an hindex of 4, co-authored 4 publications receiving 618 citations.
Papers
More filters
Journal ArticleDOI
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Paolo A. Ascierto,Dirk Schadendorf,Carola Berking,Sanjiv S. Agarwala,Carla M.L. van Herpen,Paola Queirolo,Christian U. Blank,Axel Hauschild,J. Thaddeus Beck,Annie St-Pierre,Faiz Niazi,Simon Wandel,Malte Peters,Angela Zubel,Reinhard Dummer +14 more
TL;DR: MEK162 is the first targeted therapy to show activity in patients with NRAS -mutated melanoma and might offer a new option for a cancer with few effective treatments.
Journal ArticleDOI
Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations.
Paolo A. Ascierto,Carola Berking,Sanjiv S. Agarwala,Dirk Schadendorf,Carla M.L. van Herpen,Paola Queirolo,Christian U. Blank,Axel Hauschild,J. Thaddeus Beck,Angela Zubel,Faiz Niazi,Simon Wandel,Reinhard Dummer +12 more
TL;DR: This open label, phase II study assessed the antitumor activity of MEK162 in patients (pts) with BRAFV600 and NRAS mt advanced cutaneous melanoma by administering orally at a starting dose of 45 mg twice daily.
Journal ArticleDOI
A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors.
Philippe L. Bedard,Josep Tabernero,Razelle Kurzrock,Carolyn D. Britten,Anastasios Stathis,Jose Perez-Garcia,Angela Zubel,Ngocdiep T. Le,Kirsten Carter,Kevin M. Bellew,Chiara Gallarati,Faiz Niazi,David Demanse,Stefan De Buck,Cristiana Sessa +14 more
TL;DR: The MAPK and PI3K/AKT signaling pathways regulate proliferation, differentiation and cell death in human cancers and known interaction between the 2 pathways provides the rationale for co-expression of these pathways in mice.
Journal ArticleDOI
Overall Survival and Biomarker Results From a Phase 2 Study of MEK1/2 Inhibitor Binimetinib (MEK162) in Patients With Advanced NRAS-Mutant Melanoma
C.M.L. van Herpen,Sanjiv S. Agarwala,Axel Hauschild,R. Dummer,Carola Berking,J.T. Beck,Dirk Schadendorf,G. Gibney,Rob L. H. Jansen,Paola Queirolo,P.A. Ascierto,Christian U. Blank,Heidi Nauwelaerts,Faiz Niazi,Rupam Ranjan Pal,A. Reddy,V. Antona,Angela Zubel,Michael Heinrich +18 more
TL;DR: Binimetinib 45mg bid is active in NRAS-mutant melanoma with an acceptable safety profile and the hypothesis that constitutive CDK4/6 pathway signaling may play a role in resistance is suggested.